Qihong Xu

发表

Spermatocyte‐specific expression of the gene for mouse testis‐specific transcription elongation factor S‐II

Takahiro Ito, H. Takeuchi, T. Kubo, 1996, FEBS letters.

Dysfunction of D2 dopamine receptor expressing neurons underlies manic-like behaviors in mice modeling SHANK3 duplication disorder

Zhandong Liu, H. Zoghbi, D. Standaert, 2021 .

Potent Antitumor Activity of AP24534, An Orally Active Inhibitor of Bcr-Abl, Flt3 and Other Kinases, in Both in Vitro and in Vivo Models of Acute Myeloid Leukemia (AML)

T. Clackson, L. Berk, V. Rivera, 2008 .

Potent Antitumor Activity of AP24534, an Orally Active Inhibitor of Bcr-Abl Variants Including T315I, in In Vitro and In Vivo Models of Chronic Myeloid Leukemia (CML).

T. Clackson, B. Druker, A. Corbin, 2007 .

Abstract #3738: Discovery of potent and selective orally active inhibitors of anaplastic lymphoma kinase (ALK)

T. Clackson, R. Anjum, V. Rivera, 2009 .

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.

T. Clackson, B. Druker, A. Corbin, 2009, Cancer cell.

B-cell delivered gene transfer of human S-Ag-Ig fusion protein protects from experimental autoimmune uveitis.

D. Scott, Z. Karabekian, R. Caspi, 2006, Clinical immunology.

Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant.

Wei-Sheng Huang, Jan Romero, Shuangying Liu, 2010, Journal of medicinal chemistry.

Identification, synthesis, and biological evaluation of novel pyrazoles as low molecular weight luteinizing hormone receptor agonists.

R. Murray..., C. Jorand-Lebrun, Weishui Weiser, 2007, Bioorganic & medicinal chemistry letters.

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.

T. Clackson, R. Anjum, V. Rivera, 2016, Journal of Medicinal Chemistry.

Crystal Structure of the T315I Mutant of Abl Kinase

T. Zhou, W. Shakespeare, Sarah D. Lamore, 2007, Chemical biology & drug design.

Structural Mechanism of the Pan‐BCR‐ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance

T. Clackson, V. Rivera, T. Zhou, 2011, Chemical biology & drug design.

Functionally Biased D2R Antagonists: Targeting the β-Arrestin Pathway to Improve Antipsychotic Treatment.

Patrick W. Faloon, Jen Q. Pan, F. A. Schroeder, 2018, ACS chemical biology.

9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation.

G. Daley, T. Clackson, M. Azam, 2009, Journal of medicinal chemistry.

Orally Active Inhibitors of the Imatinib Resistant Bcr-Abl Mutant T315I.

T. Clackson, B. Druker, A. Corbin, 2006 .

Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant.

Wei-Sheng Huang, Jan Romero, Shuangying Liu, 2011, Bioorganic & medicinal chemistry letters.

Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors.

T. Clackson, T. Sawyer, W. Shakespeare, 2008, Bioorganic & medicinal chemistry letters.

Multiplex quantitative assays indicate a need for reevaluating reported small-molecule TrkB agonists

M. Palmer, E. Holson, Yan-ling Zhang, 2017, Science Signaling.

A new tinman-related gene, nkx2.7, anticipates the expression of nkx2.5 and nkx2.3 in zebrafish heart and pharyngeal endoderm.

Kyu-Ho Lee, R. Breitbart, K. Lee, 1996, Developmental biology.

Structural Mechanism of the Pan‐BCR‐ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance

T. Clackson, V. Rivera, T. Zhou, 2011, Chemical biology & drug design.